Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ORGANIZATION
FPMAJ Begins Survey on Lifting of Shipment Restrictions
The Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ) has launched a survey to look into issues around the lifting of shipment restrictions requested by regulatory authorities for 130 APIs that are deemed to be available on the market in…
To read the full story
Related Article
- FPMAJ Investigating Supply Status for 60% of All Drugs, Tally Due Out by Year-End
September 14, 2022
- Shipment Curbs Remain for Over 40% of Drugs Despite Sufficient Supply Volumes: FPMAJ Survey
June 24, 2022
- Shipment Curbs Lifted for Only 49 Products by End of 2021 after MHLW Request: FPMAJ Survey
March 25, 2022
- Govt-Industry Arrangement for Drug Supply Survey Hits Rough Waters; FPMAJ Stands Pat on Continued Dialogue
February 10, 2022
ORGANIZATION
- Biotech Group Calls for Post-IPO Startups to Get AMED Support
August 19, 2026
- EFPIA Executive Hails Japan’s Honebuto as “Blueprint” for Europe
August 17, 2026
- New Chuikyo Pharmacist Rep Urges 2027 Revision to Stay within 4-Minister Deal
August 3, 2026
- Ectopic Fat Research Group Launches to Push Cross-Disciplinary Studies
July 31, 2026
- JPMA Chief Seeks Concrete Reforms to Reward Innovation after Honebuto
July 31, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…